Oxford, Moderna develop cancer vaccine
Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 09, 2026
This medical breakthrough could significantly impact the pharmaceutical and biotechnology sectors, potentially leading to new revenue streams for Moderna>>> and enhancing the reputation of the University of Oxford. The success of this vaccine could also open doors for mRNA technology in preventing other cancers, creating a new market segment. The stock price of Moderna>>> could see a positive impact due to this development.
The University of Oxford and pharmaceutical firm Moderna>>> have developed a pioneering mRNA vaccine, mRNA-4194, aimed at preventing bowel and ovarian cancers in individuals with Hereditary nonpolyposis colorectal cancer>>>. A clinical trial, named Intercept-Lynch, is set to launch this summer to assess the vaccine's ability to train the immune system to recognize and eliminate pre-cancerous cells. This initiative marks Moderna>>>'s first foray into cancer prevention using its mRNA technology. Hereditary nonpolyposis colorectal cancer>>>, affecting approximately one in 300 people in England, significantly increases the risk of various cancers. Professor David Cox>>>, the lead investigator, believes the vaccine could be transformative and provide insights generalizable to other cancer types. Cancer Research UK>>> has backed the vaccine's development. The second phase of the study, involving multiple centers across the United Kingdom>>>, is expected to begin in 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard